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Abstract
Glycogen storage disease type IIIa (GSDIIIa) is an inborn error of carbohydrate
metabolism caused by a debranching enzyme deficiency. A subgroup of
GSDIIIa patients develops severe myopathy. The purpose of this study was to
investigate whether acute nutritional ketosis (ANK) in response to ketone-
ester (KE) ingestion is effective to deliver oxidative substrate to exercising mus-
cle in GSDIIIa patients. This was an investigator-initiated, researcher-blinded,
randomized, crossover study in six adult GSDIIIa patients. Prior to exercise
subjects ingested a carbohydrate drink (~66 g, CHO) or a ketone-ester
(395 mg/kg, KE) + carbohydrate drink (30 g, KE + CHO). Subjects performed
15-minute cycling exercise on an upright ergometer followed by 10-minute
supine cycling in a magnetic resonance (MR) scanner at two submaximal
workloads (30% and 60% of individual maximum, respectively). Blood metabo-
lites, indirect calorimetry data, and in vivo 31P-MR spectra from quadriceps
muscle were collected during exercise. KE + CHO induced ANK in all six sub-
jects with median peak βHB concentration of 2.6 mmol/L (range: 1.6-3.1). Sub-
jects remained normoglycemic in both study arms, but delta glucose
Abbreviations: 31P-MR, 31 phosphorus magnetic resonance; βHB, beta-hydroxybutyrate; AcAc, acetoacetate; ANK, acute nutritional ketosis; COV,
coefficient of variation; CPET, cardio-pulmonary exercise test; FAO, fatty acid oxidation; FFAs, free fatty acids; GDE, glycogen debranching enzyme;
GSD, glycogen storage disease; GSDIIIa, glycogen storage disease type IIIa; HMPs, hexose-mono-phosphates; KE, ketone-ester; PCr, phosphocreatine;
Pi, inorganic phosphate; RER, respiratory exchange ratio; RPE, rate of perceived exertion; RQ, respiratory quotient; VO2max, maximum oxygen
uptake; Wmax, maximal workload.
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Take home message: This investigator-initiated, randomized, crossover study has revealed favorable effects of acute nutritional ketosis during
submaximal cycling exercise in adult glycogen storage disease type IIIa patients with a severe myopathic phenotype.
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concentration was 2-fold lower in the KE + CHO arm. The respiratory
exchange ratio did not increase in the KE + CHO arm when workload was
doubled in subjects with overt myopathy. In vivo 31P MR spectra showed a
favorable change in quadriceps energetic state during exercise in the KE
+ CHO arm compared to CHO in subjects with overt myopathy. Effects of
ANK during exercise are phenotype-specific in adult GSDIIIa patients. ANK
presents a promising therapy in GSDIIIa patients with a severe myopathic
phenotype.
Trial registration number: ClinicalTrials.gov identifier: NCT03011203.
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1 | INTRODUCTION
Glycogen storage disease type IIIa (GSDIIIa; OMIM
#232400) is an inborn error of carbohydrate metabolism
caused by pathogenic variants in the AGL gene, resulting
in impaired glycogen debranching enzyme (GDE) activity
in liver, cardiac, nerve, and muscle tissue. According to
the International Study on GSDIII (ISGSDIII), most
patients present before the age of 1.5 years with various
combinations of hepatomegaly, failure to thrive and
fasting intolerance.1 Biochemically, the phenotype is
characterized by fasting ketotic hypoglycemia, postpran-
dial hyperlactatemia, increased transaminases, and
hyperlipidemia.2
Dietary management to maintain normoglycemia and
prevent hyperketonemia is the mainstay of treatment in
GSDIIIa patients. Specifically, it involves designed dosing
and frequency of a high-protein diet with cornstarch sup-
plementation.3,4 However, despite such dietary manage-
ment, 52% of patients report exercise intolerance and 31%
suffer from proximal myopathy in an observational,
international multicenter study of a relatively young
patient cohort.1 Therefore, these percentages could even
be an underestimation of the actual burden in adulthood.
Moreover, progression of myopathy with age is observed
by muscle ultrasound and dynamometry.5,6 Although
longitudinal studies are lacking, the available evidence
suggests a shift from an acute, fasting-intolerance-
associated hepatic phenotype in childhood toward a
chronic, skeletal muscle, and hepatic phenotype in adult
GSDIIIa patients.7,8
The pathophysiology underlying muscle dysfunction
in GSDIIIa patients is still incompletely understood. Vari-
ous disease mechanisms have been proposed. First, the
primary GDE deficiency together with high carbohydrate
intake could cause excessive storage of an abnormal gly-
cogen structure (ie, limit dextrin) in muscle interfering
with contractile function.9-11 Second, increased endoge-
nous proteolysis of skeletal muscle to provide adequate
amino acids as gluconeogenic substrate to the liver could
contribute to muscle wasting.12 Last, in vivo findings of
delayed intramuscular metabolic recovery postexercise in
a study in GSDIIIa patients suggest that myopathic symp-
toms may also result from cellular energy crisis during
exercise as a result of reduced mitochondrial capacity for
oxidative ATP synthesis.13
To date, physical training remains the most effective
approach to prevent and reverse progressive loss of skel-
etal muscle mass and muscle quality.14 Any safe transla-
tion of this concept to the management of GSDIIIa
patients is, however, severely complicated by the fact
that GDE deficient muscles rely more on the metabo-
lism of blood glucose than intramuscular glycogen for
oxidative ATP synthesis.15 Moderate concentrations of
ketone bodies beta-hydroxybutyrate (βHB) and
acetoacetate (AcAc) in the bloodstream may provide
exercising muscles with an alternative external source of
oxidative fuel than blood glucose.16 In 2012, an edible
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ketone-ester ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate;
KE) for human application was described that can
achieve acute nutritional ketosis (ANK) via oral inges-
tion without any sodium loading.17 In trained athletes,
oral KE ingestion resulted in glycogen sparing during
exercise, and a slight enhancement of endurance exer-
cise performance and recovery.18,19 Recently, oral KE
ingestion prior to exercise was shown to be effective to
deliver oxidative substrate to exercising leg muscle and
improve intramuscular energy balance during sub-
maximal cycling exercise in patients with a fatty acid
oxidation (FAO) defect.20
Here, this matter was further investigated. Specifi-
cally, we investigated if ANK in response to KE ingestion
is equally effective in adult patients with GSDIIIa to
deliver oxidative substrate to exercising muscle with
favorable effects on intramuscular energy balance state
during submaximal exercise.
2 | SUBJECTS AND METHODS
2.1 | Study approval
The Medical Ethical Committee of the University Medi-
cal Center Groningen (UMCG), the Netherlands
approved the study protocol (ref. no. METc2016.591). The
study was conducted according to the principles of the
Helsinki Declaration of 1975 as revised in 1983. All sub-
jects provided written informed consent prior to inclu-
sion in the study.
2.2 | Subjects
Adults with GSDIIIa were recruited by the center of
expertise for hepatic GSD at the UMCG, the Netherlands
and the Faroes Hospital, Tórshavn, Faroe Islands. The
trial was conducted at the UMCG between February
2017 and March 2018. Inclusion criteria were
(a) confirmation of GSDIII with enzyme assay and/or
AGL variation analysis, GSDIIIa further specified as
GDE deficiency in muscle or clinical and/or biochemical
signs of cardiac and/or skeletal muscle involvement, and
(b) age from 18 to 65 years. Exclusion criteria included
(a) pregnancy or breastfeeding, (b) insulin-dependent
diabetes mellitus, (c) recent cardiac disease (including
cardiomyopathy, coronary artery disease, or a positive
history for angina pectoris), (d) contraindications for
magnetic resonance imaging studies, (e) unable to per-
form bicycle exercise, and (f) intercurrent illness which
may influence exercise tolerance. Figure S2 presents the
participant flow chart.
2.3 | Study design
This was an investigator-initiated, randomized,
researcher-blinded, comparator-controlled, two-way cross-
over study (NCT03011203). Three consecutive study visits
were scheduled at the UMCG, after written informed con-
sent. Foreign subjects stayed in a hotel close to the study
site during the whole study period. Other subjects stayed
in the hotel the night before study visit 2 and 3.
2.4 | Procedures
Figure S1 presents the study protocol.
2.4.1 | Study visit 1: Screening visit
General history, physical examination, muscle ultrasound,
dynamometry and plasma analysis of liver transaminases,
total creatine kinase, and NT-proBNP were performed.
The activity level was assessed by the International Physi-
cal Activity Questionnaire.21 Muscle ultrasound and dyna-
mometry were performed and analyzed as described
previously.6 Z-scores for muscle ultrasound density of the
biceps, quadriceps, calf (gastrocnemius and/or soleus),
and tibialis anterior muscles were calculated based on
age-related references values.22 After at least 2 hours of
rest subjects performed a cardio-pulmonary exercise test
(CPET) to determine subjects' individual maximal work-
load (Wmax) and maximum oxygen uptake (VO2max).
2.4.2 | Study visit 2/3: Exercise protocol
with prior ingestion of study drink
Subjects fulfilled an identical exercise protocol during
visits 2 and 3, which were separated by 7 days in all sub-
jects. Subjects were asked to refrain from alcohol and
caffeine for 24 hours prior to each study visit and to con-
sume a similar breakfast in the morning of both study
visits. A 3-day food diary was collected prior to visit 2
and 3. At 8:00 AM, a taxi brought the subject to the study
site. Here the subject was transported in a wheelchair to
minimize exercise before study procedures. After gen-
eral instructions and positioning for exercise, the subject
was given the study drink at approximately 9:00 AM
(t = 0). Forty-five minutes after study drink ingestion,
the subject started with a 15-minute upright bicycle pro-
tocol. The target pedaling frequency was 70 rounds per
minute (rpm). During the upright bicycle protocol, indi-
rect caloric and heart rate measurements were collected
(Cosmed K4, Lode Excalibur). Ratings of perceived
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exertion (RPE) were assessed with the Borg scale.23
After the 15-minute upright bicycle protocol, subjects
started 10 minutes of cycling inside the MR scanner. In
each exercise bout, workload was increased from 30% to
60% of the subject's individual Wmax for the last
5 minutes. Blood was sampled via an intravenous cathe-
ter at baseline, during upright bicycle exercise, during
supine exercise inside the MR scanner, and 3 hours after
exercise. Samples were directly analyzed for βHB, AcAc,
glucose, insulin, lactate, and free fatty acids (FFAs) by
standard laboratory procedures. Urine was collected in
the time between study drink ingestion and until 3 hours
after exercise.
2.5 | Outcome measures
The primary outcome measures were blood βHB and
glucose concentrations, exercise performance, as
assessed with indirect caloric and heart rate measure-
ments, and 31 phosphorus magnetic resonance (31P-MR)
spectra during exercise and recovery. The 31P-MR spec-
troscopy permits continuous and noninvasive monitor-
ing of inorganic phosphate (Pi), phosphocreatine (PCr),
and pH, allowing assessment of muscle energy metabo-
lism during exercise.24 Secondary outcomes were blood
concentrations of AcAc, insulin, lactate, and FFAs, RPE
scores, and urinary excretion of βHB and glucose
tetrasaccharide (Glc4). Glc4 was analyzed by LC-MS/MS
according to,25 with minor adjustments.25
2.6 | Investigational product
Study drinks were prepared at the study site 1 hour
before ingestion. Subjects received 395 mg/kg of KE
+ 30 g maltodextrin (KE + CHO) or an isocaloric car-
bohydrate drink containing only maltodextrin ~66 g
(CHO). In both study arms, a minimum of 1.2 g of
carbohydrate per minute exercise supply was
ensured.26,27
2.7 | Randomization and blinding
Subjects were randomly assigned to a study drink
order based on enrollment. The researcher (J. A. L.J.)
who analyzed the 31P-MRS data was blinded for study
drink randomization. Ingestion and preparation of
study drink took place in another study room to guar-
antee blinding for this researcher. All data sets from
31P-MR spectra were coded for blinded analysis by one
researcher (I. J. H.).
2.8 | 31P-MRS analysis
2.8.1 | 31P-MRS data acquisition
In vivo 31P-MR spectroscopic data on quadriceps energy
and pH balance at rest, during exercise and postexercise
were collected using a 3.0 Tesla whole-body MR-scanner
fitted with a supine cycle ergometer (Achiva; Philips
Healthcare, Best, The Netherlands) and analyzed
according to methods described elsewhere.28 Dynamic
acquisition of 31P-MR spectra during 10-minute cycling
exercise at 70 to 80 rpm was synchronized with motion
using custom-built ergometer-spectrometer interfacing
hardware and software as described elsewhere.29 The
brake-weight required for workload equivalents of 30%
and 60% of Wmax, respectively, was calculated for each
subject as described elsewhere.30
2.8.2 | 31P-MRS data processing
Data were processed and analyzed in the time domain
using the AMARES algorithm in the public jMRUI soft-
ware environment (version 3.0) in combination with prior
knowledge information on ATP metabolite content and
31P-MR spectral properties as described elsewhere (see
also Figures S3-S5).29 Intramuscular pH was determined
from the resonance frequency of Pi using standard
methods.29 Postexercise kinetics of Pi recovery to resting
levels were analyzed by nonlinear curve-fitting of a mono-
exponentially function yielding a fitted estimate of recov-
ery time constant (in seconds) as described elsewhere.29
2.9 | Statistical analysis
Data were analyzed using SPSS Statistics version 23.0
(IBM Corp., Armonk, New York) and visualized using
Prism 5 software (GraphPad Software, Inc., La Jolla, Cali-
fornia). Data from indirect calorimetry were processed
using Matlab version 2019a (MathWorks, Inc., Natick,
Massachusetts). A linear mixed model was used to ana-
lyze the effect of study drink on blood metabolites. Fixed
effects in this model were the main effects of study arm,
time, workload, and order of the study drinks in the
cross-over design as well as the two-way interactions
between study arm and workload and study arm and
time and the three-way interaction between study arm,
time, and workload. Subject ID was included in the
model as a random effect. Post hoc contrast analyses were
performed to determine the effect of study drink per time
point. Descriptive statistics were used for remaining out-
come parameters and a two-tailed paired Student's test
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was used for statistical differences in 31P-MRS data. Data
were considered statistically significant at P < .05.
3 | RESULTS
3.1 | Subjects
Six GSDIIIa (4F, 2 M) patients from four different coun-
tries were enrolled with a median age of 46 years (range:
36-63). Table 1 presents the characteristics of study sub-
jects. The outcomes of muscle ultrasound, dynamometry,
and CPET showed a severe myopathic phenotype in sub-
ject #1, 2, and 3. Subject #2 presented with a lower leg
support device to stabilize his right foot, while subject #3
needed a companion for walking support. MR images of
the upper legs showed severe muscle atrophy and fat
replacement in subject #1 and #3. In contrast, subjects
#4, 5, and 6 had normal muscle tests and CPET out-
comes. Also, urinary Glc4 concentrations were markedly
lower in these subjects. Due to this large heterogeneity
between subjects, results will be presented in two groups
or individually. Group 1 includes subjects #1, 2, and
3 with overt myopathy, and group 2 includes subjects #4,
5, and 6 without overt myopathy.
3.2 | Tolerance of KE and ANK
KE was well tolerated by all subjects. One subject (#2)
reported mild headache after ingestion of KE + CHO
(maximum βHB concentration in this patient reached
2.8 mmol/L). The other subjects did not report any symp-
toms of nausea, headache, or stomach pain after inges-
tion of the KE + CHO drink. No adverse events were
reported.
3.3 | Effect of ANK on blood and urine
metabolites
Figure 1 presents the concentration kinetics of selected
blood metabolites throughout the study protocol in both
study arms. Ingestion of KE + CHO induced significant
ANK within 1 hour (Figure 1A,B). Peak βHB and AcAc
concentrations were on average 2.6 mmol/L (range:
1.6-3.1) and 1.0 mmol/L (range: 0.7-1.2), respectively
(Figure 1A,C). Median βHB concentrations at t = 0
ranged from 0.0 to 0.4 mmol/L in the CHO arm and from
0.0 to 0.7 mmol/L in the KE + CHO arm. Four hours
after ingestion of KE + CHO median βHB concentration
was 0.5 mmol/L (n = 5, range: 0.1-0.8). All subjects
remained normoglycemic in both study arms (glucose
concentrations >3.6 mmol/L, Figure 1D), but glucose
concentrations were higher throughout the exercise pro-
tocol after ingestion of CHO vs KE + CHO (t = 50;
P < .0001, t = 60, t = 105, t = 110; P < .01; linear mixed
model, Figure 1D). The average delta of glucose concen-
trations was almost 2-fold higher in the CHO arm vs the
KE + CHO arm, specifically 4.7 mmol/L vs 2.6 mmol/L (-
Table S1). Workload did not affect glucose concentrations
differently between study arms. Insulin concentrations
were lower at t = 50 and t = 105 in the KE + CHO arm
(P < .05; linear mixed model, Figure 1E). Lactate concen-
trations increased from baseline into exercise, but there
were no differences between study arms at different
timepoints (P > .05; linear mixed model, Figure 1F).
FFAs in blood remained low throughout the study proto-
col in both arms (Figure 1G) and were influenced by
lunch 3 hours postexercise. Urinary myoglobin concen-
trations were within the local reference range (<21 μg/L)
in both study arms in five out of six subjects. In subject
#1, urinary myoglobin concentration was slightly
increased after KE + CHO ingestion, namely 34 μg/L,
but not after CHO. No symptoms or signs of acute rhab-
domyolysis were reported by the study subjects during
the phone calls the day after study visit 2 and 3.
3.4 | Effect of ANK on cardiorespiratory
parameters during exercise
Figure 2 shows the results of heart rate and indirect
caloric measurements in both study arms of all sub-
jects (n = 6). Median (range) RPE scores were 7 (6-9)
and 7 (6-8) at 30%Wmax, and 9 (7-13) and 10 (7-14) at
60%Wmax with and without ANK, respectively. Heart
rate increased on average from 70 at rest (upright posi-
tion on ergometer) to 100 bpm at 30% Wmax to
130 bpm at 60% Wmax in both study arms
(Figure 2A). The respiratory exchange ratio (RER) was
1.0 at rest and decreased to 0.8 to 0.9 during exercise
at 30% Wmax in both arms (Figure 2B, Table S2). Dur-
ing exercise at 60% Wmax, RER went back up to 1.0
only in the CHO arm (Figure 2B). Comparing mea-
sured RER values during exercise between overt (#1,
2, and 3) and nonovert myopathic subjects (#4, 5, and
6), no difference was found in the CHO arm
(Figure 2C). However, in the KE + CHO arm, RER
seems to decrease more from rest to 30% Wmax in
nonovert myopathic subjects than in overt myopathic
subjects (Figure 2C). Specifically, RER during exercise
at 30%Wmax in nonovert myopathic patients was 0.86
compared to 0.96 in overt myopathic patients
(Figure 2C). In the KE + CHO arm, RER did not
change when workload was increased from 30% to 60%
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Wmax in subjects with overt myopathy. The coefficient
of variation (COV; SE/mean) of RER was 2- to 3-fold
lower in the KE + CHO arm than in the CHO arm in
both groups (Figure 2C).
3.5 | Effect of ANK on in vivo quadriceps
energy balance during cycling exercise
All subjects without overt myopathy (subjects #4,
5, and 6) completed the supine cycling exercise task
inside the MR scanner. Due to technical difficulties, the
data of the CHO arm collected during exercise could
not be analyzed for subject #5. Of the three subjects
with overt myopathy (subjects #1, 2, and 3), only sub-
ject #1 was able to complete the regular in-magnet
exercise task. Subject #3 performed an adapted exercise
task consisting of propelling the ergometer flywheel
without any mechanical braking (“idle” resistance of
the ergometer) due to insufficient leg muscle power.
Subject #2 was unable to perform any form of supine
cycling exercise in the MR scanner due to foot flexor
paralysis.
Pi/PCr ratios are useful measures of muscle mito-
chondrial function, where a decrease in Pi/PCr ratio
reflects improved mitochondrial efficacy. Figure 3A shows
the measured Pi/PCr ratio in the quadriceps muscle of
subject #1, #4, #6, and #5 during exercise at two sub-
maximal workloads in both study arms. At 30% Wmax,
the Pi/PCr ratio measured in the presence of ANK was
lower than in the CHO arm in three subjects (subject #1,
4, and 6; Figure 3A, left panel). At 60% Wmax, quadri-
ceps Pi/PCr ratio measured in the presence of ANK in
subject #1 was likewise lower than in the CHO arm, but
not in subjects without overt myopathy (subjects #4 and
6; Figure 3A, right panel). Mild muscle alkalosis was
observed during exercise at both workloads in subject #1
in both study arms. In subject #4, this was found only in
the CHO arm (Table S3).
Figure 3B shows the results of the in vivo 31P-MR
measurements in quadriceps muscle during in-magnet
cycling exercise for subject #3. In the CHO arm, this sub-
ject was able to maintain cycling exercise for 162 seconds
(Figure 3B). The 31P-MR spectrum of this patient at
exhaustion showed that the intramuscular PCr store was
almost completely depleted concomitant with millimolar
accumulation of hexose-monophosphates (HMPs) in con-
tracting fibers (Figure 3B). In the KE + CHO arm, the
patient was able to maintain cycling exercise for
229 seconds—that is, 67 seconds longer than in the CHO
arm (Figure 3B). The 31P-MR spectrum of the quadriceps
muscle at exhaustion in the KE + CHO arm was almost









































































































































































































































































































































FIGURE 1 Changes of blood and urine metabolites after ingestion of either carbohydrates (CHO) or carbohydrates and ketone-ester
(KE + CHO) drink before, during, and after exercise. A, βHB kinetics after ingestion of KE + CHO; B, βHB concentrations; C, AcAc
concentrations; D, glucose concentrations; E, insulin concentrations; F, lactate concentrations; and G, FFA concentrations. In panel (B-G),
n = 4 for time points t = 105 and t = 110 (during in-magnet exercise), n = 6 for all other time points in both study arms. Light gray columns
represent the time frame of exercise at 30% Wmax, dark gray columns represent the time frame of exercise at 60% Wmax. Values expressed
as mean ± SEM. *P < .05, §P < .01, ±P < .0001; linear mixed model analysis with post hoc contrast analysis. βHB, beta-hydroxybutyrate;
FFA, free fatty acid
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of cycling in the CHO arm (Figure 3B) except for two par-
ticulars: (a) the amplitude of the HMP signals at exhaus-
tion in the presence of ANK was lower than in the CHO
arm (Figure 3B); (b) muscle pH at exhaustion was mildly
alkalotic in the presence of ANK compared to mildly
acidic in the CHO arm (Table S4, Figure S3-S5).
3.6 | Effect of ANK on postexercise
metabolic recovery kinetics
Figure 3C shows a typical example of time course of
intramuscular Pi immediately following exercise. In
four out of five subjects, the rate of metabolic recov-
ery, indexed by the time constant tau of Pi recovery
toward resting level (τPi; in seconds), was almost
2-fold slower than previously reported for healthy
human quadriceps muscle (Figure 3C, table).30 Within
the accuracy of τPi estimation, there were no individ-
ual differences in rate of metabolic recovery between
study arms.
4 | DISCUSSION
This study in six adults with GSDIIIa investigated
whether ANK in response to oral ingestion of a KE can
supply oxidative substrate to exercising muscle. ANK was
efficiently induced within 1 hour after ingestion of KE
+ CHO, KE was well tolerated, and improved glucose
homeostasis. We obtained in vivo evidence that ANK has
a beneficial effect on muscle energy balance during exer-
cise in GSDIIIa patients with a severe muscle phenotype.
In patients without any overt muscle phenotype, we
found no beneficial effect on muscle energy balance.
In the present study, the ingestion of 395 mg/kg KE
in subjects with GSDIIIa resulted in ANK with maximum
βHB concentrations (1.6-3.1 mmol/L) comparable to
those previously found in healthy adults18,31 and patients
with Very Long-Chain acyl-CoA Dehydrogenase defi-
ciency (VLCADD).20 Subjects remained normoglycemic
in the KE + CHO arm during the entire protocol. Fur-
thermore, the delta in glucose concentration was almost




FIGURE 2 Heart rate and indirect calorimetry measurements at rest, 30% Wmax, and 60% Wmax during the upright bicycle protocol
in both study arms. A,B, Pooled data (n = 6); C, Data presented as subgroups based on muscle phenotype, n = 3 in both groups. Dashed line
represents the RQ of βHB (0.89). Data presented as mean ± SD. βHB, beta-hydroxybutyrate; RQ, respiratory quotient




FIGURE 3 Legend on next page.
10 HOOGEVEEN ET AL.
lower insulin concentrations. The latter may well have
been the direct result of the 2-fold higher maltodextrin
intake in the CHO study arm. This amount of CHO sup-
plementation (~66 g) was comparable to a previous fruc-
tose supplementation study in GSDIIIa patients.32
The whole-body indirect calorimetry results con-
firmed that subjects performed exercise at submaximal
workloads, with peak heart rates around 130 bpm at the
highest imposed workload. When stratifying for muscle
phenotype, a striking finding was that the COV was 2- to
3-fold lower in the KE + CHO arm compared to the
CHO arm in both groups—that is, subjects with overt
myopathy (#1-3) and subjects without overt myopathy
(#4-6) (Figure 2C). On a whole body level, ANK was asso-
ciated with a more consistent metabolic state than CHO
alone. The particular trend observed in the CHO arm in
both groups, fitted well with the “cross over” concept of
whole-body oxidative substrate utilization during incre-
mental exercise—that is, predominantly fatty-acid oxida-
tion at workloads below 40%Wmax progressively shifting
toward CHO oxidation at higher workloads.33 In subjects
without overt myopathy, this trend in RER was also
observed in the KE + CHO arm. In subjects with overt
myopathy, however, RER did not increase with workload
change from 30% to 60% suggesting incomplete non-CHO
substrate utilization. This could be either βHB (RQ 0.9)
or a mix of fat (RQ 0.7) and βHB.18
Complete data sets on in vivo energy and pH balance
in exercising quadriceps muscle in both study arms were
obtained in three subjects. In vivo intramuscular Pi/PCr
ratios during exercise at the lowest workload in each
arm suggested that leg muscle of these subjects used
ketones as oxidative substrate in the KE + CHO arm.
Previously, Kim et al found a small reduction of in vivo
Pi/PCr ratio of the myocardium in dogs infused with
βHB compared to control.34 In subject #1, a relatively
large reduction in Pi/PCr ratio in the KE + CHO com-
pared to CHO arm was observed at both 30% and 60%
Wmax equivalents (Figure 3A). It is unlikely that this
was solely the result of improved thermodynamic effi-
ciency of oxidative ATP synthesis by ketone oxidation.
Rather it may well reflect that recruitment of fewer
motor units was needed to perform the voluntary exer-
cise task during ANK due to improved work efficacy.35
Indeed, subject #3 was able to perform the same
voluntary exercise task almost 1 minute longer in the
KE + CHO arm than in the CHO arm. The in vivo 31P
spectrum at exhaustion recorded in the CHO arm
showed large accumulation of phosphorylated glycolytic
intermediates as well as mild muscle acidification, both
of which were absent in the KE + CHO arm
(Figure 3B). In subjects #4 and #6, we did not find any
favorable effect of ANK on muscle energy balance dur-
ing exercise at the highest submaximal workload. Last,
ANK did not have any effect on postexercise metabolic
recovery kinetics (Figure 3C) similar to previous find-
ings in VLCADD patients.20 This was an expected out-
come as it has previously been shown that these
kinetics are independent of end-exercise state of muscle
energy balance for low-to-moderate exercise work-
loads.36 However, the postexercise recovery time of Pi in
quadriceps muscle of the subjects was on average 2-fold
slower than previously reported in healthy controls
(Figure 3C, table). This result was in close agreement
with previous 31P MRS findings in calf muscle of GSDIII
patients13
On basis of these results, we conclude that ANK dur-
ing exercise induced by prior KE ingestion may be benefi-
cial to GSDIIIa patients when engaging in physical
activity. Specifically, the results of this study suggest that
such therapeutic approach should principally be focused
on patients with a severe muscle phenotype, exemplified
by subjects #1 to 3 in this study. Nevertheless, long-term
follow-up studies are needed in more patients to assess
efficacy and safety. Here it may be important to note that
subjects #4 to 6 all originated from and resided in the
same North-Atlantic archipelago with a known founder
pathogenic variation,37 whereas subjects #1 to 3 all origi-
nated from different countries in Europe. This prompts
consideration of genetic and environmental modifying
factors contributing to the observed differences in muscle
phenotype in GSDIIIa. Subjects #1 to 3 carry unique non-
sense AGL genotypes which involves at least one duplica-
tion or deletion, whereas the homozygous nonsense
single-base substitution c.1222C>T (R408X) AGL geno-
type in subjects #4 to 6 causes truncation of enzyme,
which affects both enzymatic functions, namely oligo-1,-
4-1,4-glucanotransferase and amylo-1,6-glucosidase.37 It
is therefore likely that additional genetic or dietary fac-
tors may explain the phenotypes. Interestingly, average
FIGURE 3 Outcomes of in vivo 31P-MR spectra of quadriceps muscle during 10-minute supine in-magnet exercise and recovery in
both study arms. A, Intramuscular Pi/PCr ratios at equivalents of 30% and 60% Wmax in four subjects; B, Exercise duration and related
spectra, in both study arms for subject #3; C, Example of intramuscular Pi recovery time course from subject #3 in the KE + CHO arm
(left panel), table represents individual rates of metabolic recovery vs healthy controls30 (right panel). 31P-MR, 31 phosphorus magnetic
resonance; CHO, carbohydrates; KE, ketone-ester; PCr, phosphocreatine; Pi, inorganic phosphate
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daily protein intake of subjects #4 to 6 was up to 2-fold
higher than reported by subjects #1 to 3 (Table 1). A
recent study in AGL knock-out mice demonstrated a
reduction in muscle wasting in mice fed a high protein
and glucose restricted diet.11 Various case studies have
also demonstrated a reversal of myopathy defined by
increased physical strength and reduced CK concentra-
tions after dietary interventions with high protein10,38
and/or ketogenic diets.39,40 These studies report different
outcome measures and macronutrient distributions;
hence, it remains an enigma whether muscle atrophy in
adult GSD IIIa patients can be prevented by dietary
interventions.
The generalizability of our findings is subject to sev-
eral limitations. Like other clinical studies in patients
with ultra-rare disease, this study was complicated by dif-
ficulties of including sufficient subjects. Despite the
demanding study protocol, we were able to recruit six
patients from four different countries, reflecting the wide
spectrum of clinical heterogeneity between adult GSDIIIa
patients. The latter prompted the analysis of two n = 3
subgroups rather than one n = 6 population. Due to this
small number of subjects and the great heterogeneity
between individual GSDIIIa patients, definitive conclu-
sions on the efficacy of ANK cannot be drawn for the
whole cohort. The intervention was constrained by
the absence of a negative control group because of the
requirement of a “sufficient” amount of CHO in both
study arms to ensure patient safety. This issue was dis-
cussed during a focus group meeting with patients,
resulting in a decision to have safety arguments outweigh
methodological arguments. Similarly, muscle biopsy was
offered as an optional procedure in our protocol, similar
to Cox18 and Bleeker.20 However, cross-sectional MR
images of the upper leg showed that any chance of suc-
cessful sampling of muscle tissue from the leg of subjects
#1 and #3 by non-guided transcutaneous needle biopsy
would be slim (Table 1). Of the four remaining subjects,
only one subject (#2) gave informed consent. Last,
although the subjects exercised with increased plasma
concentrations of glucose (CHO) and ketones (KE
+ CHO), we cannot exclude that differences in absorp-
tion and requirement of maltodextrin vs KE in GSDIIIa
patients may have caused different maximum plasma
concentrations.
For decades, several descriptive studies have under-
lined the importance of investigation of muscle involve-
ment in GSDIIIa patients,1,9,41,42 besides progressive liver
disease.7 Prevention and, if possible, reversal of progres-
sive loss of skeletal muscle mass and quality in GSDIIIa
patients is therefore a key objective in clinical manage-
ment. Current guidelines on GSDIII management do not
provide recommendations regarding exercise or pre-
exercise therapy4 but do mention the potential beneficial
effect of aerobic conditioning as seen in McArdle's dis-
ease (GSDV; OMIM #232600).43 The recent international
GSD priority setting partnership has added muscle prob-
lems to the list of research priorities for GSD patients.44
Valayannopoulos et al reported successful treatment of
sodium-D,L-3-hydroxybutyrate up to 800 mg/(kg d), in
conjunction with a ketogenic and high-protein diet, in a
2-month-old infant with GSD IIIa, complicated by severe
cardiomyopathy.45 We recently reported decreased crea-
tine kinase concentrations and a decrease in cardiac
hypertrophy in pediatric GSDIIIa patients after the intro-
duction of high fat diets.46 The current study of oral KE
supplementation on in vivo muscle biochemistry and
function in GSDIIIa patients provides a subsequent
steppingstone toward translation of the theoretical bene-
ficial effect of ANK to a pre-exercise skeletal muscle ther-
apy in selected, myopathic GSDIIIa patients.
Furthermore, ANK with oral supplementation is less
demanding than a restrictive, ketogenic diet. As such, we
propose to study acute delivery of ketones as alternative
to acute glucose or fructose supplementation15,32 to sup-
port physical activity in this subgroup of GSDIIIa
patients. Strict patient-to-patient interventions and long-
term monitoring of muscle status together with liver
function and morphology are recommended in case of
frequent use of KE to induce ANK.47
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